Corruption in Pharmaceuticals – International Perspective 10 – Blog Post #504 by Asrar Qureshi
Dear Colleagues! This is Pharma Veterans Blog Post #504. Pharma Veterans welcomes sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi onWordPress, the top blog site. Please email to email@example.com for publishing your contributions here.
Continued from Previous…… This series is based on a report compiled by Jilian Clare Cohen1, Monique Mrazek2, and Loraine Hawkins3 for World Bank.
Six decision points were identified where corruption could infiltrate. The first was manufacturing, second was marketing authorization, third was selection, fourth was procurement, fifth was distribution, sixth was drug prescribing and dispensing.
Selected Strategies to Mitigate Corruption in Pharmaceutical Systems
The report goes on to make recommendations for certain strategies to mitigate the risk of corruption. It is more like an indicative list which can be modified for particular use.
The list is arranged as per the six decision points which are vulnerable to corruption. For greater relevance to our country situation, I have added the column of Pakistan Status.[Quote]
As can be seen from the table above, Pakistan does not have procedures and policies in some key areas.
In the next blog post, which will be the last of this series, we shall sum up the entire discussion done so far.
To be Continued……
Disclaimer. Most pictures in these blogs are taken from Google Images which does not show anyone’s copyright claim. However, if any such claim is presented, we shall remove the image with suitable regrets.
- Jilian Clare Cohen – Toronto, Canada
- Monique Mrazek – Latin America
- Loraine Hawkins – London